13,502 Shares in Merus (NASDAQ:MRUS) Bought by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new stake in Merus (NASDAQ:MRUS) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,502 shares of the biotechnology company’s stock, valued at approximately $675,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Deerfield Management Company L.P. Series C lifted its holdings in shares of Merus by 3.8% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 2,749,401 shares of the biotechnology company’s stock valued at $162,682,000 after purchasing an additional 100,000 shares in the last quarter. Federated Hermes Inc. increased its position in shares of Merus by 6.7% during the second quarter. Federated Hermes Inc. now owns 2,398,800 shares of the biotechnology company’s stock worth $141,937,000 after acquiring an additional 150,000 shares in the last quarter. Samlyn Capital LLC increased its position in shares of Merus by 11.9% during the second quarter. Samlyn Capital LLC now owns 2,324,195 shares of the biotechnology company’s stock worth $137,523,000 after acquiring an additional 247,605 shares in the last quarter. Driehaus Capital Management LLC raised its holdings in shares of Merus by 26.4% during the second quarter. Driehaus Capital Management LLC now owns 1,550,009 shares of the biotechnology company’s stock worth $91,714,000 after acquiring an additional 323,518 shares during the period. Finally, Lynx1 Capital Management LP lifted its position in Merus by 32.9% in the 1st quarter. Lynx1 Capital Management LP now owns 1,509,007 shares of the biotechnology company’s stock valued at $67,951,000 after acquiring an additional 373,782 shares in the last quarter. 96.14% of the stock is owned by institutional investors and hedge funds.

Merus Trading Down 6.2 %

NASDAQ MRUS opened at $46.58 on Monday. The firm has a market capitalization of $3.19 billion, a P/E ratio of -11.79 and a beta of 1.12. The firm’s fifty day moving average price is $50.96 and its two-hundred day moving average price is $51.94. Merus has a 1 year low of $22.26 and a 1 year high of $61.61.

Merus (NASDAQ:MRUS) last issued its earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The firm had revenue of $11.77 million during the quarter, compared to the consensus estimate of $9.11 million. On average, research analysts anticipate that Merus will post -3.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Needham & Company LLC reissued a “buy” rating and issued a $85.00 price target on shares of Merus in a research note on Friday, November 1st. HC Wainwright reissued a “buy” rating and issued a $85.00 target price on shares of Merus in a research report on Friday, November 1st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $67.00 price target on shares of Merus in a research report on Thursday, July 25th. Guggenheim lifted their price objective on shares of Merus from $93.00 to $111.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Finally, Canaccord Genuity Group raised shares of Merus to a “strong-buy” rating in a research report on Thursday, July 25th. One investment analyst has rated the stock with a sell rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Merus currently has an average rating of “Buy” and an average price target of $86.70.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.